Adverse drug reactions

Coleman, Jamie J.; Pontefract, Sarah

doi:10.7861/clinmedicine.16-5-481

Cited by 283 publications

(197 citation statements)

References 16 publications

(13 reference statements)

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…There may be various explanations for differences in ADR rates between studies including differences in data collection methods and ADR definitions. In general, however, the numbers indicate a point of concern since ADRs may be bothersome and may reduce treatment adherence, efficacy, quality of life and increase healthcare costs …”

Section: Introductionmentioning

confidence: 99%

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study

Vries

Denig

Ekhart

et al. 2019

Brit J Clinical Pharma

112

View full text Add to dashboard Cite

Aims We aimed to assess and characterize sex differences in adverse drug reactions (ADRs) reported to the national pharmacovigilance centre in the Netherlands while considering differences in drug use. Methods ADRs spontaneously reported by healthcare professionals and patients to the Netherlands pharmacovigilance centre Lareb were used. Drug–ADR combinations reported at least 10 times between 2003–2016 for drugs used by ≥10,000 persons in that period were included. Data about the number of drug users was obtained from the National Health Care Institute. Sex‐specific ADRs, like gynaecological problems, were excluded. Sex differences in specific drug–ADR combinations were tested using bivariate logistic regression analyses in which the number of drug users per sex was taken into account. Results In total, 2483 drug–ADR combinations were analysed. Possibly relevant sex differences were shown in 363 combinations (15%). Most of these drug–ADR combinations were reported more often for women (322 combinations). Drugs with the highest number of ADRs that were more often reported for women included thyroid hormones (32 combinations) and antidepressants (16 combinations for the centrally acting sympathomimetics; 14 combinations for other antidepressants). Some ADRs were predominantly reported for women across a range of drugs such as headache and dizziness whereas other ADRs such as tendon ruptures and aggression were reported more often for men. Conclusions Identified sex differences in reported ADRs often referred to women. These differences may have various causes, including pharmacological and behavioural causes, which need to be further assessed. The results may ultimately lead to sex‐specific prescribing or monitoring recommendations.

show abstract

Section: Introductionmentioning

confidence: 99%

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study

Vries

Denig

Ekhart

et al. 2019

Brit J Clinical Pharma

112

View full text Add to dashboard Cite

show abstract

“…On the other side of the Atlantic Ocean, in Sweden, fatal ADRs were estimated as a comparable public health burden, the seventh most common cause of death (Wester et al, 2008). Studies undertaken on drug safety over the past three decades have collectively shown that ADRs are common in clinical practice, occurring in about 5-10% of patients and resulting in unscheduled hospitalizations, or occurring during hospital stay or after discharge from the hospital (Coleman and Pontefract, 2016). It is important to note that ADRs are often underreported in clinical practice.…”

Section: Why Personalized Medicine? Why Now?mentioning

confidence: 99%

Digging Deeper into Precision/Personalized Medicine: Cracking the Sugar Code, the Third Alphabet of Life, and Sociomateriality of the Cell

Özdemir

Arğa

Aziz

et al. 2020

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Precision/personalized medicine is a hot topic in health care. Often presented with the motto ''the right drug, for the right patient, at the right dose, and the right time,'' precision medicine is a theory for rational therapeutics as well as practice to individualize health interventions (e.g., drugs, food, vaccines, medical devices, and exercise programs) using biomarkers. Yet, an alien visitor to planet Earth reading the contemporary textbooks on diagnostics might think precision medicine requires only two biomolecules omnipresent in the literature: nucleic acids (e.g., DNA) and proteins, known as the first and second alphabet of biology, respectively. However, the precision/personalized medicine community has tended to underappreciate the third alphabet of life, the ''sugar code'' (i.e., the information stored in glycans, glycoproteins, and glycolipids). This article brings together experts in precision/personalized medicine science, pharmacoglycomics, emerging technology governance, cultural studies, contemporary art, and responsible innovation to critically comment on the sociomateriality of the three alphabets of life together. First, the current transformation of targeted therapies with personalized glycomedicine and glycan biomarkers is examined. Next, we discuss the reasons as to why unraveling of the sugar code might have lagged behind the DNA and protein codes. While social scientists have historically noted the importance of constructivism (e.g., how people interpret technology and build their values, hopes, and expectations into emerging technologies), life scientists relied on the material properties of technologies in explaining why some innovations emerge rapidly and are more popular than others. The concept of sociomateriality integrates these two explanations by highlighting the inherent entanglement of the social and the material contributions to knowledge and what is presented to us as reality from everyday laboratory life. Hence, we present a hypothesis based on a sociomaterial conceptual lens: because materiality and synthesis of glycans are not directly driven by a template, and thus more complex and open ended than sequencing of a finite length genome, social construction of expectations from unraveling of the sugar code versus the DNA code might have evolved differently, as being future-uncertain versus future-proof, respectively, thus potentially explaining the ''sugar lag'' in precision/personalized medicine diagnostics over the past decades. We conclude by introducing systems scientists, physicians, and biotechnology industry to the concept, practice, and value of responsible innovation, while glycomedicine and other emerging biomarker technologies (e.g., metagenomics and pharmacomicrobiomics) transition to applications in health care, ecology, pharmaceutical/diagnostic industries, agriculture, food, and bioengineering, among others.

show abstract

“…When identifying uses of the concept, seven articles defined adverse reaction to medications as effects or events associated to any situation involving medication use (Alhawassi, Krass, Bajorek, & Pont, ; Chen et al., ; Coleman & Pontefract, ; Ho, Le, Thai, & Taewijit, ; Muringazuva et al., ; Riedl & Casillas, ; Wooten, ). Three defined it as reactions that occur with the proper use of a medication and standard doses (Asscher, Parr, & Whitmarsh, ; Su, Chung, & Hung, ; Vervloet & Durham, ).…”

Section: Evaluation Of Findingsmentioning

confidence: 99%

“…In the present study, antecedents for adverse reaction to medications were identified in 29 articles (Table ). On the other hand, consequences are outcomes of the concept, such as quality of life impairment, economic impact, death, hospital admission, and morbidity (Chen et al., ; Coleman & Pontefract, ; Onder et al., ; Su et al., ). Clinical manifestations can also be experienced, for example, acute renal failure, hypotension, arrhythmia, cutaneous reaction, gastrointestinal complaints, falls, electrolyte disorder, anemia, infections, and bleeding (Alsbou et al., ; Coleman & Pontefract, ; Davies et al., ; Muñoz‐Torrero et al., ; O'Connor, Gallagher, Byrne, & O'Mahony, ; Onder et al., ; Passarelli, Jacob‐Filho, & Figueras, ; Rashed et al., ; Shah et al., ; Smyth et al., ).…”

Section: Evaluation Of Findingsmentioning

confidence: 99%

“…The final step is determining the empirical referents, which demonstrate the occurrence of the concept in the clinical practice. Some articles used the same validated scale for evaluating the probability and causality of adverse reactions to medications (Alsbou et al., ; Andrade, Lobo, & da Silva, ; Shah, Gajjar, & Desai, ; Coleman & Pontefract, ; Davies et al., ; Harugeri, Parthasarathi, Ramesh, Guido, & Basavanagowdappa, ; Mandavi, D'Cruz, Sachdev, & Tiwari, ; Muñoz‐Torrero et al., ; Onder et al., ; Passarelli et al., ). One study identified variables associated with adverse reactions, such as number of medications and history of adverse reactions, and developed a risk score, which was validated in a sample of elderly patients (Onder et al., ).…”

Section: Evaluation Of Findingsmentioning

confidence: 99%

See 1 more Smart Citation

Adverse Reactions to Medications: Concept Analysis and Development of a New Risk Nursing Diagnosis

Mantovani

Moorhead

Almeida

et al. 2019

Int J of Nursing Knowl

View full text Add to dashboard Cite

PURPOSE To analyze the concept of adverse reaction to medications and to develop the new nursing diagnosis Risk for Adverse Reactions to Medications. METHODS Concept analysis using Walker and Avant's eight step method. FINDINGS Thirty‐three articles indexed in four databases were included. The components of the new nursing diagnosis were determined, including possible nursing outcomes and interventions. CONCLUSIONS The concept analysis supported the development of the new nursing diagnosis Risk for Adverse Reactions to Medications, which may help nurses to evaluate and identify patients susceptible to adverse reactions. IMPLICATIONS FOR NURSING PRACTICE The establishment of this nursing diagnosis will provide nurses an opportunity to implement interventions to anticipate and effectively intervene with patients at risk for this condition.

show abstract

Adverse drug reactions

Cited by 283 publications

References 16 publications

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study

Digging Deeper into Precision/Personalized Medicine: Cracking the Sugar Code, the Third Alphabet of Life, and Sociomateriality of the Cell

Adverse Reactions to Medications: Concept Analysis and Development of a New Risk Nursing Diagnosis

Contact Info

Product

Resources

About